Search
  • 网站搜寻
亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。
返回搜索结果

Development of a Novel cAMP–Inhibitor that Restores Epithelial and/or Endothelial Barrier Integrity in Human Cells Infected by Pathogenic Bacteria


技术优势

The current inhibitor provides an alternative strategy for the treatment of diseases caused by anthrax, cholera or pertussis toxins.


技术应用

The inhibitor, ES109 is a potential therapeutic for the treatment of the diseases caused by anthrax, cholera or pertussis toxins and can restore, preserve, or both, epithelial and endothelial barrier integrity.


详细技术说明

Researchers at UC San Diego have developed a strategy to block the pathogenic effects of Anthrax Edema Toxin (ET) and Cholera Toxin (CT) which represent key virulence factors for the respective pathogens, Bacillus anthracis and Vibrio cholerae. These toxins disrupt vascular endothelial (ET) and intestinal epithelial (CT) barrier integrity by blocking transport of adhesion proteins such as cadherins and signaling molecules to cell-cell junctions. As discussed above, ET and CT both act to dramatically elevate cAMP levels in the cell, but by distinct mechanisms. Two well-known cAMP binding proteins mediate the effects of cAMP in host cells: protein kinase A (PKA) and EPAC, a guanine nucleotide exchange factor for the small GTPase Rap1. Our invention uses a small molecule inhibitor (ESI09) of Rap1 to protect against the barrier disruptive effects of ET and CT, and to fortify endothelial and epithelial integrity in a wide variety of medical conditions in which barrier dysfunction is an important pathophysiologic feature.


其他

State Of Development

The soluble cell permeant EPAC/Rap1 inhibitor ESI09 has been shown to dramatically inhibit ET induced edema in vivo in a mice model. Additional studies were performed using both transgenic Drosophila and mammalian systems to dissect the role of ESI09 to bind the cAMP binding site on EPAC to prevent activation of EPAC.


Intellectual Property Info

A provisional patent has been submitted and the technology is available for licensing.


Related Materials

Annabel Guichard, Prashant Jain, Mahtab Moayeri, Ruth Schwartz, Stephen Chin, Lin Zhu, Beatriz Cruz-Moreno, Janet Z. Liu, Bernice Aguilar, Andrew Hollands, Stephen H. Leppla, Victor Nizet, Ethan Bier. Anthrax edema toxin disrupts distinct steps in Rab11-dependent junctional transport. 2017. PLoS Pathog


Tech ID/UC Case

29420/2017-070-0


Related Cases

2017-070-0


国家/地区

美国

欲了解更多信息,请点击 这里
Business of IP Asia Forum
桌面版